LATITUDE - deel A
A Phase III outcomes trial that will compare the effects of losmapimod 7.5 mg twice daily (BID) for 12 weeks versus placebo when added to standard of care on the incidence of MACE in subjects with ACS (NSTEMI and STEMI).
- Stadium
- klaar
- Middel
- losmapimod
- Populatie
- ASCVD
- Fase
- III
- First Patient In
- 14 juli 2014
- Last Patient In
- -
- Last Patient Last Visit
- -
Studiedirecteur
